➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 4,767,611

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,767,611
Title: Method for affecting intracellular and extracellular electric and magnetic dipoles
Abstract:Described is a treatment of cancer and other disease processes, including infectious diseases through the use of external electromagnetic energy to alter electric and magnetic dipoles intracellularly to produce as in the case of cancer, death of the cancer cells in living tissue. The normal cells are not damaged. The process comprises introducing minute particles into the interior of cells in living tissue. These particles are capable of affecting the intracellular conductivity, dielectric properties, dipole content and membrane characteristics of the cell and nucleus. The particles are introduced intravenously, intra-arterially, and/or intra-lymphatically and the subject is then exposed to an alternating electromagnetic field to introduce energy into the interior of the cancer cells and thereby destroy the cancer cells without harming the normal cells. Further, selectivity may be achieved by incorporating specific radioisotopes or tumor specific antibodies bound to the particles. This treatment process may also be used to affect atherosclerotic lesions as well as other disease processes.
Inventor(s): Gordon; Robert T. (Skokie, IL)
Application Number:06/627,536
Patent Claims:see list of patent claims

Details for Patent 4,767,611

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Recordati Rare Diseases, Inc. PANHEMATIN hemin POWDER, FOR SOLUTION 101246 1 1983-07-20   Start Trial 2040-01-28 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.